H.B. Fuller Company (FUL) Stock Price & How to Invest

H.B. Fuller Company formulates and sells industrial adhesives, sealants and coatings from roughly 70 plants worldwide, with about 7,100 employees and trailing twelve-month revenue of ~$3.55 billion. The business runs in three segments. Hygiene, Health and Consumable Adhesives (~$422 million of revenue in the quarter ended May 30, 2026) glues diapers, tissue, food packaging, e-commerce cartons and medical devices. Engineering Adhesives (~$283 million) sells reactive, light-cure and two-part structural products into transportation, electronics, clean energy, aerospace, appliances and heavy machinery. Building Adhesive Solutions (~$245 million) covers commercial roofing, flooring, insulation, building envelope, caulks and sealants. The company has paid a quarterly dividend for 58 consecutive years and raised it for 33 straight.

The investment picture is a margin story fighting a volume problem. Pricing actions and the Quantum Leap restructuring program pushed adjusted gross margin to 34.2% in the second quarter of fiscal 2026 (up ~200 basis points) and adjusted EBITDA margin to 19.1%, yet organic growth came almost entirely from price. The third quarter (ended August 29, 2026, reported September 23) kept the pattern: revenue of ~$938 million, up ~5.2% year over year, net income of ~$79 million, and adjusted EPS of $1.52 against a ~$1.46 consensus. Shares closed at $51.75 on October 16, 2026, down ~14% year to date and ~12% over the past year, within a 52-week range of ~$46.70 to ~$68.63, for a market cap of ~$2.79 billion. Layered on top: a ~$942 million cash acquisition of UK-listed Advanced Medical Solutions, now being funded with $850 million of 7.625% notes due 2034 priced in October; an Ancora bid for the Building Adhesive Solutions segment that rose on September 29 to $1.2 billion to $1.4 billion in cash; and Engine Capital pushing for a market check of the whole company.

Leverage is the first constraint: total debt of ~$2.19 billion against ~$97 million of cash already sits near 3x trailing EBITDA of ~$610 million, and the new 7.625% notes carry a coupon well above the 4.000% notes they partly replace, so interest cost rises as the AMS deal closes. Buying a medtech business is also a step outside the industrial adhesives core, so integration and synergy delivery carry real execution risk. The margin gains lean heavily on price, which historically gives back some ground when petrochemical-derived raw material costs fall, and first-quarter results already showed supply disruption and force majeure notices from suppliers. Construction end markets served by Building Adhesive Solutions are rate-sensitive and cyclical, roughly 40% of revenue sits outside the Americas and is exposed to currency swings, and tariffs remain an unpredictable input. Finally, the activist situation can resolve in more than one direction, and an unaccepted carve-out bid, even a raised one, is not a floor under the share price.

7 analysts publish price targets on FUL, averaging $68.29 against a $51.32 price as of October 2026, or +33.1%. The published targets run from $62.00 to $80.00, a narrow spread, and the ratings split 6 buy, 1 hold, 0 sell. Over the last six months there have been 4 raises and 4 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full FUL forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on H.B. Fuller Company. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Margin expansion from pricing and Quantum Leap. Adjusted EBITDA margin reached 19.1% in the second quarter of fiscal 2026, up ~70 basis points year over year, while adjusted gross margin gained ~200 basis points to 34.2%. The most optimistic published target, $80.00, assumes this works close to its best case.

The case against. Leverage is the first constraint: total debt of ~$2.19 billion against ~$97 million of cash already sits near 3x trailing EBITDA of ~$610 million, and the new 7.625% notes carry a coupon well above the 4.000% notes they partly replace, so interest cost rises as the AMS deal closes. The most pessimistic target, $62.00, is roughly what FUL is worth if this bites instead.

Read the full bull and bear case on FUL, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see H.B. Fuller Company's investor relations page or your broker.

• Revenue (TTM): ~$3.55B; Q3 FY2026 revenue ~$938M, up ~5.2% year over year
• Q3 FY2026 (quarter ended Aug 29, 2026): Adjusted EPS $1.52 vs ~$1.46 consensus; net income ~$79M
• Margins (TTM): Gross ~32.7%, operating ~13.2%, net ~5.6%
• Net income / EPS (TTM): ~$198M; trailing EPS ~$3.59, forward EPS estimate ~$5.18
• Debt and cash: ~$2.19B debt, ~$97M cash; $850M of 7.625% notes due 2034 priced in October for AMS
• Valuation: ~$2.79B market cap at $51.75; ~14.4x trailing and ~10.0x forward earnings; ~8.0x EV/EBITDA; ~0.78x sales
• Dividend: $0.98 annualized, ~1.9% yield, ~27% payout ratio

H.B. Fuller reports on a fiscal year ending in late November, so the latest print as of October 16, 2026 is the third quarter (ended August 29), released September 23 with a modest EPS beat. Fourth-quarter results are not expected until early 2027, so the next catalysts are the AMS closing and the board's answer to Ancora's raised bid. At ~10x forward earnings and ~8x EV/EBITDA, against a mean analyst target near $68, the gap between the margin story and the volume story remains wide.

Other names that sit close to FUL: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get FUL exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so FUL sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where FUL fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

H.B. Fuller is a pricing-and-restructuring margin story running inside a soft-volume industrial, and the debate as of October 2026 is whether a roughly 8x EV/EBITDA multiple compensates for weak volumes, a debt-funded medtech acquisition and an activist bid that has climbed to as much as $1.4 billion for one segment.

Whether FUL is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is FUL a buy or a sell?, and where the stock could go from here in the FUL stock forecast.

For income investors, whether FUL pays a dividend and how the payout looks is covered in does FUL pay a dividend? And to weigh FUL against a peer, read the full side-by-side comparisons: FUL vs ROAD and FUL vs RPM.